Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03761056
Title Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kite, A Gilead Company

B-cell lymphoma


axicabtagene ciloleucel + Cyclophosphamide + Fludarabine

Age Groups: adult | senior
Covered Countries USA | FRA

Facility Status City State Zip Country Details
Banner Health MD Anderson Cancer Center Gilbert Arizona 85234 United States Details
City of Hope Duarte California 91010-3012 United States Details
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 United States Details
Vanderbilt University Medical Center Nashville Tennessee 37232 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia Details
Hopital Saint Louis Paris 75475 France Details
*Shaded cells indicate that there was no data available from for the field